Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Catalent Biologics Opens New Single-Use Biomanufacturing Center of Excellence

Published: Tuesday, April 30, 2013
Last Updated: Tuesday, April 30, 2013
Bookmark and Share
State-of-the-art cGMP facility quadruples biomanufacturing capacity, extensively utilizes single-use technology for greater flexibility and efficiency.

Catalent Pharma Solutions will officially open its new, state-of-the–art biomanufacturing Center of Excellence in Madison, WI, at a ribbon cutting ceremony on Friday, 26th April, 2013. Constructed in response to customer demand, the new facility will quadruple Catalent’s current biologics manufacturing capacity, allowing the company to extend its offerings in the sector while enhancing the efficiency and output of its proprietary GPEx® cell line engineering technology as well as other mammalian cell lines.

The official opening follows the recent announcement that Catalent has acquired an exclusive license to market Redwood Bioscience’s (www.redwoodbioscience.com) proprietary SMARTag™ precision protein-chemical engineering technology for the development of advanced antibody drug conjugates (ADCs). Redwood’s novel, site specific protein modification and linker technologies, enable the generation of homogenous bioconjugates engineered to enhance potency, safety and stability. Combined with Catalent’s proprietary GPEx cell line expression system, for the rapid development of stable, high yielding cell lines, and a broad range of analytical and fill-finish services, the new Madison facility represents a further expansion of Catalent’s capabilities to help customers develop more and better biologic treatments.

Designed for flexible cGMP production, from 10L up to 1000L, and non-GMP production up to 250L, the facility features extensive use of single-use technologies and unidirectional flow to greatly reduce cross contamination risk. Manufacturing is supported by integrated analytical, formulation development and viral clearance capabilities, small-scale and large-scale process development laboratories, and separate microbiology and Quality Control functions.

Catalent has moved all its 89 employees from its current 43,000 sq ft facility in Middleton to the 100,000 sq ft Madison site and plans on eventually employing over 100 people at the new site.
“Our new biomanufacturing Center of Excellence has been specifically designed to meet our customers’ needs through improved delivery of integrated services in the areas of biologic development and manufacturing, and we will be pleased to welcome many of them on site at the official opening,” said Barry Littlejohns, President of Catalent’s Biologics business. “The extensive application of single-use technology greatly reduces the risk of cross contamination and gives us huge flexibility and scale, while our on-site capabilities enable us to provide our customers with solutions for even the most difficult to express proteins.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Catalent To Acquire Pharmatek
The acquisition adds expanded drug development services and spray drying technology.
Wednesday, September 14, 2016
Catalent, Roche Collaborate On SMARTag™
Collaboration focuses on development of novel molecules using SMARTag technology to couple different therapeutic modalities.
Thursday, January 14, 2016
Catalent Biologics Expands Capabilities
Company announces multi-site expansion of its analytical and process development capabilities.
Thursday, November 26, 2015
Catalent Biologics Adds New Technology Platform
Company has signed an exclusive licensing agreement with Excelimmune to access ACT platform.
Thursday, July 09, 2015
Catalent Awarded Grant as Part of Vaccine Research Consortium
Goal of the consortium is to develop a scalable manufacturing process for vaccines that are stable and temperature independent.
Friday, April 24, 2015
Catalent and Valerion Therapeutics Collaborate
Collaboration to bring new treatments for orphan genetic disorders to market.
Thursday, December 04, 2014
Catalent Expands its Technology Offerings in Biologics
Company acquires Redwood Bioscience and the SMARTag™ technology platform.
Friday, October 10, 2014
Catalent Increases Stake in Redwood Bioscience
The increase follows compelling data generated by the SMARTag™ ADC platform.
Tuesday, March 25, 2014
Catalent and UMN Pharma Announce Collaboration
UMN Pharma will produce a number of biosimilars using Catalent’s GPEx cell lines.
Thursday, December 20, 2012
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
‘Cellbots’ Chase Down Cancer, Deliver Drugs Directly to Tumors
Programmable T cells shown to be versatile, precise, and powerful in lab studies.
Monkeys Protected by Zika DNA Vaccine
Experimental Zika virus DNA vaccines successfully protected monkeys against Zika infection.
New Weapon Against Hard-to-Treat Bacterial Infections
Using peptides, researchers have been able to prevent drug-resistance bacteria from forming abscesses.
Tapping Evolution to Improve Biotech Products
Researchers show how 'ancestral sequence reconstruction' can be used to guide engineering of a blood clotting protein.
Antibodies Paving the Way to HIV Vaccine
Researchers uncover factors responsible for the formation of broadly neutralizing HIV antibodies in humans.
Vaccine Against Common Cold Achievable
Researchers suggest that a vaccine against rhinoviruses is possible using variant virus vaccines.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!